###begin article-title 0
mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
 Most microRNAs have a stronger inhibitory effect in estrogen receptor-negative than in estrogen receptor-positive breast cancers 
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
Recent studies have shown that the regulatory effect of microRNAs can be investigated by examining expression changes of their target genes. Given this, it is useful to define an overall metric of regulatory effect for a specific microRNA and see how this changes across different conditions.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 314 315 314 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 492 494 492 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 560 562 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 896 901 896 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 905 910 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer</italic>
###xml 952 954 952 954 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 960 962 960 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Here, we define a regulatory effect score (RE-score) to measure the inhibitory effect of a microRNA in a sample, essentially the average difference in expression of its targets versus non-targets. Then we compare the RE-scores of various microRNAs between two breast cancer subtypes: estrogen receptor positive (ER+) and negative (ER-). We applied this approach to five microarray breast cancer datasets and found that the expression of target genes of most microRNAs was more repressed in ER- than ER+; that is, microRNAs appear to have higher RE-scores in ER- breast cancer. These results are robust to the microRNA target prediction method. To interpret these findings, we analyzed the level of microRNA expression in previous studies and found that higher microRNA expression was not always accompanied by higher inhibitory effects. However, several key microRNA processing genes, especially Ago2 and Dicer, were differentially expressed between ER- and ER+ breast cancer, which may explain the different regulatory effects of microRNAs in these two breast cancer subtypes.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 125 127 125 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 137 139 137 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 207 209 207 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
The RE-score is a promising indicator to measure microRNAs' inhibitory effects. Most microRNAs exhibit higher RE-scores in ER- than in ER+ samples, suggesting that they have stronger inhibitory effects in ER- breast cancers.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
MicroRNAs (miRNAs) are a class of small noncoding (19- to 24-nucleotide) RNAs that regulate the expression of target mRNAs at the post-transcriptional level [1,2]. In higher eukaryotic organisms, it is estimated that miRNAs account for about 1% of genes and regulate the expression of more than 30% of mRNAs [3].
###end p 10
###begin p 11
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 747 752 747 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">let-7</italic>
###xml 803 806 803 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS</italic>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 895 902 895 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-15 </italic>
###xml 906 912 906 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-16</italic>
###xml 959 964 959 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2 </italic>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1174 1179 1174 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1348 1355 1348 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1356 1358 1356 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 179 185 <span type="species:ncbi:9606">humans</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 1120 1125 <span type="species:ncbi:9606">human</span>
It has been shown that miRNAs play critical roles in a variety of biological processes such as cell proliferation [4], apoptosis [5], development [6], and differentiation [7]. In humans, strong links between cancer and miRNA deregulation have been suggested by recent studies [8,9]. A lot of known miRNAs are found to be located in the fragile sites (regions with high frequencies of copy number alterations in cancers) of human chromosomes, indicating that many miRNAs may be linked to carcinogenesis [10]. Furthermore, it has been shown that aberrant expression of miRNAs contributes to carcinogenesis by promoting the expression of proto-oncogenes or by inhibiting the expression of tumor suppressor genes. For instance, the down-regulation of let-7, which represses expression of the proto-oncogene RAS, has been found in a large proportion of lung cancer specimens [11]. Other examples are miR-15 and miR-16, which repress the anti-apoptotic factor gene BCL2 in chronic lymphocytic leukemia [12]. In addition, some recent studies suggest that expression profiles of miRNAs are informative for the classification of human cancers. Based on miRNA-expression profiles, Lu et al. [13] reported the classification of 334 leukemia and solid cancers that agrees well with the developmental lineage and differentiation state of the tumors. Rosenfield et al. [14] demonstrated that by using miRNA as biomarkers, tumors can be classified into subclasses according to their primary origins. Nowadays, miRNAs are thought of as promising biomarkers for cancer diagnosis and prognosis.
###end p 11
###begin p 12
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 975 982 975 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 983 985 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1060 1071 1060 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 1050 1055 <span type="species:ncbi:10090">mouse</span>
###xml 1060 1070 <span type="species:ncbi:7227">Drosophila</span>
It has been proposed that animal miRNAs regulate gene expression mainly by inhibiting translation of their target mRNAs [15,16]. More recent studies, however, have demonstrated that expression regulation at the mRNA level (via mRNA degradation or deadenylation) also serves as a critical mechanism for miRNA function in animals [17-23]. Over-expression of miRNA in cell lines cause moderate down-regulation of a large number of transcripts, many of which contain the complementary sequences of the over-expressed miRNA in their 3' untranslated regions (UTRs) [23]. Conversely, gene expression analysis from miRNA knockdown animals reveals that miRNA recognition motifs are strongly enriched in the 3' UTRs of up-regulated genes, but depleted in the 3' UTRs of down-regulated genes[20]. Motivated by these findings, several studies have demonstrated the effectiveness of investigating miRNA regulation by examining their target mRNA expression levels [24-27]. For example, Yu et al. [27] show that miRNA targets have lower expression levels in mature mouse and Drosophila tissues than in embryos via global analysis of miRNA target gene expression.
###end p 12
###begin p 13
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 420 422 420 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 428 429 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 605 607 605 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 613 615 613 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 769 771 769 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 777 779 777 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1056 1058 1056 1058 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1064 1066 1064 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 289 294 <span type="species:ncbi:9606">women</span>
In this study, we investigate differential miRNA regulation between estrogen receptor (ER) positive (ER+) and negative (ER-) breast cancers by examining changes in the expression of the miRNAs' target genes. Breast cancer is a common disease, ranking first in terms of annual mortality in women worldwide [28]. According to the ER status and responsiveness to estrogen, breast cancer can be divided into two subtypes: ER+ and ER-. The links between miRNA expression and breast cancer have been shown using miRNA microarray techniques [13,29]. Specifically, the differential expression of miRNAs between ER+ and ER- breast cancers has been investigated in [30-32]. In comparison with the large number of mRNA expression datasets [33-41], miRNA expression datasets for ER+ and ER- breast cancer are still limited. Moreover, results and conclusions from these studies are generally not consistent and sometimes even conflicting [30-32]. In this study, we take advantage of those mRNA expression datasets to investigate differential miRNA regulation between ER+ and ER- breast cancers.
###end p 13
###begin p 14
###xml 223 225 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 479 481 479 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 596 598 596 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 608 610 608 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 690 692 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1023 1028 1023 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago1 </italic>
###xml 1032 1037 1032 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 1178 1180 1178 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1190 1192 1190 1192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1317 1319 1317 1319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
For each miRNA, we calculate a regulatory effect (RE)-score, which measures the expression difference between the targets and non-targets of the miRNA in an expression profile. Then, we compare the RE-scores of miRNAs in ER+ tumor samples with their RE-scores in ER- samples to identify microRNAs with changing RE-scores (which we term RE-changing microRNAs). We applied our method to five independent microarray datasets that include gene expression profiles for both ER+ and ER- samples. In all of them, our results indicate that the majority of RE-changing miRNAs showed higher RE-scores in ER- than in ER+ samples, suggesting stronger inhibitory effects of miRNAs on their targets in ER- breast cancer. To check the robustness, we performed the same analyses using different miRNA target prediction methods, RE-score calculation methods, and RE-changing miRNA identification thresholds and obtained consistent results. Moreover, we examined the expression levels of genes in the miRNA biogenesis pathway and found that Ago1 and Ago2 (which encode argonautes, the key proteins forming the RNA-induced silencing complex (RISC)) had significantly higher expression levels in ER- than in ER+ breast cancer. This may suggest higher RISC activities and, therefore, that miRNAs down-regulate target gene expression in ER- breast cancer with higher efficiency.
###end p 14
###begin title 15
Results and discussion
###end title 15
###begin title 16
###xml 47 49 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 55 57 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Identification of RE-changing miRNAs between ER+ and ER- breast cancers
###end title 16
###begin p 17
###xml 718 720 718 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 726 728 726 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 892 894 892 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1019 1021 1019 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1162 1164 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1217 1218 1217 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
To measure the inhibitory effect of a miRNA, we calculate the RE-score, denoted as the difference of average ranks between the miRNA's non-target and target genes. It should be noted that the RE-scores for different miRNAs may not be directly comparable because the miRNAs regulate different sets of target genes. However, we can compare the RE-scores for the same miRNA in different conditions (that is, using different expression profiles). A higher RE-score indicates lower expression levels of target genes and, thereby, a stronger inhibitory effect of the corresponding miRNA. Given a breast cancer microarray dataset, we calculate the RE-scores for each miRNA in all samples. Then, we compare the RE-scores in ER+ and ER- samples to identify miRNAs that show different regulatory effects between these two breast cancer subtypes. We refer to these miRNAs as RE-changing miRNAs. Using ER+ as the reference, some RE-changing miRNAs show stronger inhibitory effects, while others show weaker inhibitory effects in ER- breast cancer. The false discovery rate (FDR) was estimated using a similar method to the significance analysis of microarrays (SAM) method [42]. A flow diagram of our analysis is shown in Figure 1.
###end p 17
###begin p 18
###xml 82 84 82 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 90 92 90 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 253 255 253 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 259 260 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 285 287 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 367 369 367 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 383 385 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Schematic diagram showing the method for identifying RE-changing miRNAs between ER- and ER+ breast cancer samples. For each miRNA in each sample, a RE-score is calculated by comparing average ranks of its target and non-target genes. RE-changing miR (ER- > ER+) and RE-changing miR (ER- < ER+) represent miRNAs that have significantly higher and lower RE-scores in ER- compared to ER+ samples, respectively. RE-invariant miR represents miRNAs that show no significant difference in RE-scores between these samples. Note that many miRNAs share the same target mRNA, while many mRNAs can also be targeted by the same miRNA, which constitutes a complex miRNA-mRNA network.
###end p 18
###begin title 19
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Most miRNAs show stronger inhibitory effects in ER- than in ER+ breast cancer
###end title 19
###begin p 20
###xml 140 142 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 944 946 944 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 955 956 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1008 1010 1008 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1016 1018 1016 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1174 1176 1174 1176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1210 1211 1210 1211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1214 1216 1214 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1279 1281 1279 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1331 1339 1331 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-371 </italic>
###xml 1369 1376 1369 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1703 1711 1703 1711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-371 </italic>
###xml 1866 1868 1866 1868 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1885 1887 1885 1887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1934 1936 1934 1936 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1986 1988 1986 1988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1997 1998 1997 1998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2005 2007 2005 2007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2057 2059 2057 2059 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2084 2086 2084 2086 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 2141 2143 2141 2143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 2192 2200 2192 2200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-371 </italic>
###xml 2230 2232 2230 2232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 2249 2257 2249 2257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-371 </italic>
###xml 2324 2326 2324 2326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
We applied our analysis to 5 carefully selected large scale microarray datasets, each containing at least 30 expression profiles for both ER+ and ER- breast cancer samples. Among these datasets, four were measured by one-channel Affymetrix GeneChips and one was measured by two-channel cDNA arrays (see Materials and methods for details about these datasets). For each dataset, we calculated the RE-scores of each miRNA in all samples. To do this, we needed to determine the target and non-target gene sets for miRNAs. Several computational methods have been developed to identify microRNA targets and predictions using these can be considerably different (Additional data file 1, the distribution of miRNA target gene numbers for different prediction tools). In our analysis, the target genes for miRNAs were predicted using the PITA algorithm, which has been shown to have high prediction accuracy [43]. Subsequently, we computed t-scores (ER- versus ER+) to measure the difference between RE-scores for ER- and ER+ samples. A positive t-score for a miRNA suggests that this miRNA has higher overall RE-scores and, thereby, stronger inhibitory effects on its targets in ER- samples. Conversely, a negative ER-/ER+ t-score indicates a stronger inhibitory effect of a miRNA in ER+ samples. For example, to estimate the RE-score of miR-371 in a sample from the HE (Hess et al. [44]) dataset, we first grouped the total 14,327 genes in the HE dataset into two sets, one with 2,054 target genes and the other with 12,273 non-target genes. Second, we sorted the expression levels of the 14,327 genes and computed the average ranks of the 2,054 targets and 12,273 non-targets, respectively. The RE-score for miR-371 in each sample was calculated as the average rank of the non-targets minus the average rank of the targets. We performed the RE-score calculation for 82 ER+ samples and 51 ER- samples and found that the RE-scores for the ER- samples are significantly higher than those for ER+ samples (t-test, P = 3.74E-15). We also compared the RE-scores for ER+ samples with those for ER- samples in the other four datasets. As shown in Figure 2a, in all of the five datasets, the RE-scores for miR-371 are significantly higher in ER- samples. Namely, miR-371 represses the expression of its target mRNAs more efficiently in ER- breast cancers. In the next section we discuss the results based on other miRNA target prediction methods.
###end p 20
###begin p 21
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 97 101 97 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 128 135 128 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-371</italic>
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-371 </italic>
###xml 187 189 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 199 201 199 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 319 323 319 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 387 389 387 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 395 397 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 485 487 485 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 512 514 512 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 688 690 688 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 700 702 700 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 711 715 711 715 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 783 785 783 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1165 1172 1159 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1173 1175 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1185 1192 1179 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1193 1195 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1203 1210 1197 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1211 1213 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1230 1234 1224 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">al. </italic>
###xml 1235 1237 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1249 1256 1243 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1257 1259 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Comparison of RE-scores between ER+ and ER- samples from five breast cancer expression datasets. (a) Box plots of RE-scores for miR-371. miR-371 shows significantly higher RE-scores in ER- than in ER+ samples for all five datasets. The statistical significance level of difference (FDR) for each dataset is also shown. (b) Distributions of the t-scores for RE-score comparison between ER- and ER+ samples. The t-scores for 470 miRNAs were calculated by comparing their RE-scores for ER- samples with those for ER+ samples. The t-score distributions for the five datasets are shown in different colors. Most t-scores are positive, indicating that most miRNAs exhibit higher RE-scores in ER- than in ER+ samples. (c) Proportion of RE-changing miRNAs with higher inhibitory effect in ER- samples (red) and RE-changing miRNAs with lower inhibitory effect in ER- samples (green) at three different significance levels (FDR </= 0.05, FDR </= 0.10, and FDR >/= 0.20). The number on the top of a bar represents how many RE-changing miRNAs were identified from the corresponding mRNA microarray dataset. HE, MI, MN, VA and WA represent the microarray data published by Hess et al. [44], Miller et al. [38], Minn et al. [39], van't Veer et al. [34], and Wang et al. [40], respectively.
###end p 21
###begin p 22
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 24 26 24 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 85 87 85 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 96 98 96 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 225 227 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 237 239 237 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 610 617 608 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 618 620 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 635 642 633 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 643 645 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 658 665 656 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 666 668 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 690 697 688 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 698 700 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 779 781 777 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 820 822 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 957 959 955 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1081 1083 1079 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1097 1099 1095 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1225 1227 1223 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 1242 1243 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 115 120 <span type="species:ncbi:9606">human</span>
We calculated the ER-/ER+ t-scores (measuring the difference between RE-scores for ER- versus ER+ samples) for 470 human miRNAs in all of the 5 datasets. Interestingly, we found that most miRNAs exhibit higher RE-scores in ER- than in ER+ samples, as suggested by the distributions of their t-scores in Figure 2b. We calculated the significance of the t-scores based on the permutation test using a similar method to SAM [42] (see Materials and methods for detail). At the 0.05 significance level (FDR </= 0.05), we identified 109, 188, 15 and 306 RE-changing miRNAs from a total of 475 miRNAs in the HE (Hess et al. [44]), MI (Miller et al. [38]), MN (Minn et al. [39]) and VA (van't Veer et al. [34]) datasets, respectively, and all of them show higher inhibitory effects in ER- breast cancer. In the WA (Wang et al. [40]) dataset, we identified 377 RE-changing miRNAs, of which 373 have higher inhibitory effects and only 4 lower inhibitory effects in ER- breast cancer. This suggests that most miRNAs exhibit stronger inhibitory effects on the expression of their targets in ER- compared to ER+ breast cancer. This conclusion could still be made when we relaxed the FDR threshold to 10% and 20%, as illustrated in Figure 2c. The t-score, P-value and FDR of each miRNA for all datasets are provided in Additional data file 2.
###end p 22
###begin title 23
Use of other miRNA target prediction algorithms
###end title 23
###begin p 24
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
Next, we investigated whether similar results can be obtained using other miRNA target prediction methods. It has been shown previously that distinct miRNA prediction methods may result in considerably different target gene sets (Additional data file 1, the distribution of miRNA target numbers for different prediction tools). To rule out the possible bias introduced by PITA, we repeated our analysis using three other miRNA target prediction methods: TargetScan [3], PicTar [45] and miRanda [46]. We chose these three out of a handful of miRNA target prediction methods not only because they have been prevalently used but also because they are, in some sense, complementary to the PITA method. Almost all miRNA target prediction methods first scan the 3' UTR of transcripts for potential miRNA binding sites that are complementary to the seed region of miRNAs. TargetScan and PicTar meet stringent seed pairing criteria, whereas the criteria are moderately stringent in PITA and miRanda. To further increase the prediction accuracy, PITA takes into account the local accessibility of the potential binding sites, whereas miRanda and PicTar apply a different strategy: they filter out those miRNA binding sites in non-conserved regions. TargetScan, the most widely used prediction method, considers both site conservation and context accessibility.
###end p 24
###begin p 25
###xml 66 71 66 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a, b</xref>
###xml 127 129 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 138 140 138 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 287 289 287 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
The results based on PicTar and miRanda are illustrated in Figure 3a, b. As shown, the t-scores for RE-score comparisons for ER- versus ER+ samples are more likely to be positive values for all five datasets, suggesting that miRNAs have stronger inhibitory effects on their targets in ER- breast cancer. Since both PITA and miRanda can require moderately stringent miRNA seed:target complementarity, in order to obtain more reliable target and non-target gene sets for miRNAs, we also tried another strategy: combining the prediction results of PITA and miRanda methods. For each miRNA, we define its target genes as those predicted by both methods and its non-target genes as those predicted by neither. This will presumably decrease both false positive and false negative prediction rates. Based on this target and non-target gene set definition, we again obtain similar results, as shown in Figure 3c.
###end p 25
###begin p 26
###xml 112 116 112 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 134 138 134 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 157 161 157 161 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 195 201 195 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d-f) </bold>
###xml 572 574 572 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Distributions of the t-scores for comparison of RE-scores based on distinct miRNA target prediction algorithms. (a) PicTar algorithm. (b) miRanda algorithm. (c) Intersection of miRanda and PITA. (d-f) TargetScan algorithm where the site is conserved (d), the site context score is above -0.20 (e), and all potential targets are included (f). The t-score distributions for the five datasets are shown in different colors. The t-scores are more likely to be positive values in all five datasets, suggesting that miRNAs have stronger inhibitory effects on their targets in ER- breast cancer.
###end p 26
###begin p 27
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1210 1212 1210 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1218 1220 1218 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1268 1270 1268 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1279 1281 1279 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1368 1372 1368 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d-f</xref>
###xml 1438 1440 1438 1440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
TargetScan is currently the most widely used microRNA target prediction tool, which relies on strict miRNA seed region complementarity [3,47]. In addition, the conservation of binding site, the context of the miRNA-binding site, the proximal AU composition, and proximity to sites for co-clustered miRNAs can enhance the targeting efficacy of a binding site [48]. Choosing different parameters for target prediction results in quite different performance [49]. Among the parameters, site conservation and site accessibility (measured as context score) are the two most important [50,51]. To evaluate the performance of different TargetScan cutoffs in the RE-score comparison, we chose three target sets - one in which the members have a conserved binding site, one in which the members have a context score greater than -0.20, and one that includes all potential targets - which we refer to as ConservedTS, ContextTS, and AllTS, respectively. These three TargetScan predictions are quite different. On average, 210, 765, and 2,026 targets per miRNA are predicted in ConservedTS, ContextTS and AllTS, respectively. After integrating mRNA expression data with all three target sets to compare the RE-scores in ER- and ER+ samples, we found again that the t-scores for ER- versus ER+ samples are more likely to be positive for all five datasets, as illustrated in Figure 3d-f. This demonstrates that the observation of higher RE-scores in ER- breast cancer, for most miRNAs, is not likely caused by a bias from the miRNA prediction method. Complete results based on three TargetScan predictions, miRanda, PicTar, and the intersection of PITA and miRanda can be found in Additional data file 2.
###end p 27
###begin title 28
Use of alternative methods to compare miRNA inhibitory effects
###end title 28
###begin p 29
###xml 128 130 128 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 967 969 967 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1008 1010 1008 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1019 1020 1019 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 1477 1479 1477 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 1610 1612 1610 1612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
To further substantiate our findings, we also used two alternative methods to investigate the inhibitory effects of miRNAs in ER+ and ER- breast cancers. The first method is similar to the one described above, but we use a different way to calculate the RE-scores for miRNAs in an expression profile. Instead of computing the average rank difference between the target and non-target gene sets for a miRNA, we calculate the RE-score as follows: first, calculate the relative expression levels of each gene across all of the samples by subtracting the mean and then dividing by the standard deviation; second, calculate the RE-score of a miRNA by comparing the relative expression levels of its target and non-target genes. For clarity, we will refer to these two RE-score calculation methods as rank comparison and expression comparison. Similar to what we found using the rank comparison method, RE-scores obtained using expression comparison tend to be higher in ER- samples as indicated by the t-score (ER- versus ER+) distribution (Figure 4a). These results are not dependent on the miRNA target prediction method because similar results are obtained using PITA and miRanda (complete results are given in Additional data file 3). As a matter of fact, the t-scores obtained by using expression comparison and rank comparison are highly correlated. For example, for the VA dataset, these two methods yield two sets of t-scores with a correlation coefficient of 0.928 (Figure 4b). As shown, 432 out of 466 miRNAs have positive t-scores from both methods, confirming stronger inhibitory effects of miRNAs in ER- breast cancer.
###end p 29
###begin p 30
###xml 97 101 97 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 338 342 338 342 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">al. </italic>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
Results obtained from an alternative RE-score calculation method based on expression comparison. (a) Distributions of the t-scores calculated by comparing the RE-scores from the expression comparison method. The employed target prediction algorithm was PITA. The t-score distributions for the five datasets are shown in different colors. (b) Correlation between the t-scores obtained from the two different RE-score calculation methods. The microarray dataset used was VA, published by van't Veer et al. [34]. The correlation coefficient (R) is 0.928, indicating that the t-scores obtained using expression comparison and rank comparison are highly correlated.
###end p 30
###begin p 31
###xml 119 126 119 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 179 181 179 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 187 189 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 846 848 846 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 930 932 930 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1090 1091 1090 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1194 1196 1194 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
The other method, referred to as ARR (adapted ranked ratio), is similar to the ranked ratio (RR) method proposed by Yu et al. [27]. First, the expression levels of each gene in ER+ and ER- samples were compared and a t-score (ER+/ER-) was calculated to measure the expression differentiation of the gene in the two breast cancer subtypes. The t-scores for all genes were then ranked and genes were divided into two groups, those with high t-scores and those with low t-scores. For each miRNA, the ARR value was calculated by dividing the number of target genes in the 'low' ranked group by the 'high' ranked group. The ARR value is an indicator of the distribution of a miRNA's targets within all genes. A low ARR value (ARR < 1) indicates that a miRNA has more targets in genes with higher t-scores, that is, genes that are lowly expressed in ER- samples; the target genes of this miRNA tend to have lower expression levels in ER- breast cancer. We calculated the ARR values for all miRNAs in each of these five datasets. The numbers of miRNAs with ARR < 1 and ARR > 1 are listed in Table 1. As shown, more miRNAs have ARR < 1 in all datasets, indicating their stronger inhibitory effect in ER- breast cancer.
###end p 31
###begin p 32
Number of miRNAs with ARR < 1 and ARR > 1 in each dataset
###end p 32
###begin p 33
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 520 522 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 528 530 528 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 867 874 867 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 990 992 990 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 998 1000 998 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Although the ARR method is similar to the RR method described by Yu et al. [27], they differ in some ways. The RR value for a miRNA in a tissue is calculated by dividing the number of targeted genes with 'low' expression by the number of target genes with 'high' expression after the expression levels of each gene across a series of tissues are ranked and split into 'high' and 'low' groups, with half the genes in each. In our ARR method, we first performed a t-test to compare the expression levels of each gene in ER+ and ER- samples. The t-scores were ranked and genes were divided into two groups corresponding to high ranked and low ranked genes, each containing half the genes. The ARR value of each miRNA was then calculated by dividing the number of targets with high rank by the number of targets with low rank. Compared with the RR method described by Yu et al. [27], our method is different in three aspects. First, for each gene, the expression levels were compared between ER+ and ER- samples. To reveal the expression difference between two groups, the t-score is more effective than the ranks across all samples. Second, the ARR value from our method is actually an indicator of difference between the expression distribution of a microRNA's target genes and that of all genes. Therefore, it directly reflects the regulatory effect of a microRNA on its target genes. Third, for a microRNA, only one ARR value is obtained based on the whole dataset with our method, and the ARR value facilitates a global inspection of the inhibitory activity differences of a microRNA between two sample groups.
###end p 33
###begin p 34
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 597 599 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 697 699 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 790 791 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 794 795 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 920 922 920 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1035 1037 1035 1037 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1214 1216 1214 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1293 1295 1293 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1377 1379 1377 1379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1389 1391 1389 1391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1495 1502 1495 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-206</italic>
###xml 1568 1570 1568 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1577 1579 1577 1579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1588 1590 1588 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1743 1745 1743 1745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1751 1753 1751 1753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1779 1780 1779 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1851 1853 1851 1853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1859 1861 1859 1861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1886 1893 1886 1893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1894 1896 1894 1896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
Although the calculations of RE-score and ARR value are completely different, the results from each are highly consistent. We compared the RE-scores determined by expression comparison methods with the ARR results. First, we computed the Spearman correlation of the RE-scores and the ARR values for each microarray dataset. As illustrated in Table 2, the inhibitory activities calculated by these two different methods are highly correlated, with the correlation coefficients ranging from 0.578 to 0.861, which provides further confirmation that more microRNAs show higher inhibitory effects in ER- breast cancers. Second, we overlapped the microRNAs with higher or lower inhibitory activity in ER- cancers predicted by the RE-score and ARR values (Table 3). If a microRNA has a t-score (ER-/ER+) > 0 in the RE-score comparison and ARR < 1 in the ARR calculation, it is predicted to have higher inhibitory activity in ER- cancer by both methods, whereas a microRNA with a t-score < 0 and RR > 1 shows consistently higher activity in ER+ cancer. More than 80% of the miRNAs overlap, indicating that these two methods are in strong agreement. Furthermore, the number of miRNAs with consistently higher activity in ER- samples is much higher than the number with consistently lower activity in ER+ samples, again indicating that most miRNAs exhibit higher regulatory effects in ER- than in ER+ samples. Some significant miRNAs are identified by both methods. For example, it has been reported that miR-206, which regulates the estrogen receptor, has higher activity in ER- than ER+ cancers [52]. In our calculations, for all five microarray datasets, the ARR values of this microRNA are all <1, and the t-scores for RE-score comparison between ER- and ER+ cancers are all >0 (Table 3). These results are consistent with the activity difference between ER+ and ER- cancer reported by Adams et al. [52].
###end p 34
###begin p 35
Correlation between the results obtained using the ARR and RE-score calculation methods
###end p 35
###begin p 36
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 149 147 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 159 161 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 396 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 563 564 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 567 568 567 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Percentage (ER- > ER+): the fraction of microRNAs with ARR < 1 and t-score < 0, indicating that the microRNAs show higher regulatory activity in ER- than in ER+ samples, as consistently supported by both the ARR method and RE-score expression comparison method. Percentage (ER- < ER+): the fraction of microRNAs with RR > 1 and t-score > 0. These microRNAs show higher regulatory activity in ER+ samples, as supported by both the ARR method and the RE-score expression comparison method. Spearman correlation: the correlation between the ARR value and t-score (ER-/ER+).
###end p 36
###begin p 37
###xml 23 31 23 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-206 </italic>
Regulatory activity of miR-206 predicted by the RE-score and ARR methods
###end p 37
###begin p 38
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
t-score (ER-/ER+): the t-score is calculated by performing a t-test to measure differentiation of the RE-scores for a miRNA in the two breast cancer subtypes. Note that here the RE-scores were calculated using the expression comparison method.
###end p 38
###begin title 39
###xml 105 107 105 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 113 115 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Differential regulatory effects of miRNAs can not be explained by miRNA expression differences between ER+ and ER- cancer
###end title 39
###begin p 40
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 152 154 152 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 281 283 281 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 289 291 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 341 348 341 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 419 421 419 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 427 429 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 478 480 478 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 577 584 577 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 600 607 600 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 637 644 637 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 757 759 757 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 775 781 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 879 881 879 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1016 1018 1016 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1025 1027 1025 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
To understand why miRNAs tend to have stronger inhibitory effects on their targets in ER- samples, we asked whether they are more highly expressed in ER- breast cancers. Using miRNA microarray technology, expression levels of miRNAs have been previously measured and compared in ER- and ER+ samples in three different studies [30-32]. Iorio et al. [31] identified 11 miRNAs that were differentially expressed between ER+ and ER- samples, of which 8 were down-regulated in the ER- samples. In contrast, many more miRNAs were reported to be differentially expressed by Blenkiron et al. [30] and Mattie et al. [32]. Specifically, Blenkiron et al. identified 35 differentially expressed miRNAs, of which 11 were up-regulated and 24 were down-regulated in the ER- samples. Mattie et al., however, reported that the majority of differentially expressed miRNAs were down-regulated in ER- samples (40 out of 43). These three miRNA expression studies do not support the idea that miRNAs tend to be more highly expressed in ER- than ER+ breast cancer. It should be noted that the three studies obtained substantially different results due to the technological issues of miRNA microarray experiments.
###end p 40
###begin p 41
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 391 398 391 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 589 591 589 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
In addition, to measure the correlation between miRNAs' inhibitory effects and their expression levels, we calculated the Spearman correlations of the t-scores for the miRNA expression comparisons and those for the miRNA RE-score comparisons. As illustrated in Table 4, there is only a very weak positive correlation between them; particularly, the miRNA expression data published by Mattie et al. [32] shows almost no correlation with the miRNA regulatory effects predicted from all five mRNA expression datasets. This further indicates that the stronger inhibitory effect of miRNAs in ER- cancer cannot be explained by their expression levels.
###end p 41
###begin p 42
Correlation between microRNA RE-scores and their expression levels
###end p 42
###begin p 43
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 183 190 183 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 203 210 203 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 221 228 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 267 274 267 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
BL and MA represent the microRNA microarray data published by Blenkiron et al. [30] and Mattie et al. [32]. HE, MI, MN, VA and WA represent the mRNA microarray data published by Hess et al. [44], Miller et al. [38], Minn et al. [39], van't Veer et al. [34], and Wang et al. [40], which were used to infer the microRNA RE-scores.
###end p 43
###begin p 44
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer</italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 312 314 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 328 330 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-103</italic>
###xml 469 477 469 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-122a</italic>
###xml 479 487 479 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-130a</italic>
###xml 489 497 489 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-148a</italic>
###xml 499 506 499 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-19a</italic>
###xml 512 519 512 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-29a</italic>
###xml 554 560 554 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 729 736 729 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 745 759 745 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mattie et al. </italic>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 828 830 828 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 846 847 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 944 950 944 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 955 957 955 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1020 1022 1020 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1028 1030 1028 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1115 1117 1115 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1133 1134 1133 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1159 1165 1159 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 1188 1190 1188 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1210 1218 1210 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-122a</italic>
###xml 1249 1255 1249 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 1298 1300 1298 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1301 1303 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1405 1407 1405 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1549 1551 1549 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1557 1559 1557 1559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Some microRNAs have large inconsistencies between their expression levels and RE-scores. For example, many studies have suggested that the expression levels of Dicer, the key gene in the generation of microRNAs, vary in different cancer subtypes [53-55]. In our study, Dicer is significantly down-regulated in ER- compared to ER+ cancers (see next section for details). A possible mechanism for this is that it is regulated epigenetically [56]. Six microRNAs, miR-103, miR-122a, miR-130a, miR-148a, miR-19a, and miR-29a, are commonly predicted to target Dicer by the prediction methods PITA, miRanda, PicTar and Targetscan. We investigated the expression levels of these microRNAs in two distinct datasets published by Blenkiron et al. [30] and Mattie et al. [32]. The expression levels of these microRNAs are mostly lower in ER- samples (Figure 5), which is opposite to our inference that they may be up-regulated to transcriptionally repress Dicer in ER- cancer. We then compared the RE-scores of these microRNAs in ER+ and ER- cancers. To our surprise, almost all microRNAs show stronger inhibitory effects in ER- cancers (Figure 5), which may explain why Dicer is expressed less in ER- cancer. Especially, miR-122a, which was reported to target Dicer and function in various cellular stresses [57,58], is expressed at significantly lower levels but shows significantly higher inhibitory activity in ER- cancer, strongly indicating that the differential regulatory effects of miRNAs can not be explained by miRNA expression differences between ER+ and ER- cancer.
###end p 44
###begin p 45
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer</italic>
###xml 142 149 142 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 273 280 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 291 298 291 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">al. </italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 337 344 337 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 431 433 431 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 439 441 439 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 574 576 574 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 624 626 624 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 770 772 770 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 778 780 778 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
The expressions and RE-scores of microRNAs predicted to target Dicer. BL and MA represent the microRNA microarray data published by Blenkiron et al. [30] and Mattie et al. [32]. HE, MI, MN, VA and WA represent the mRNA microarray data published by Hess et al. [44], Miller et al. [38], Minn et al. [39], van't Veer et al. [34], and Wang et al. [40], which were used to calculate the microRNA RE-scores. If the difference between ER+ and ER- samples is significant, the plot is flagged with three asterixes. The expression levels of these six microRNAs are mostly lower in ER- samples; however, almost all the RE-scores in ER- samples are higher, suggesting that the differential regulatory effects of miRNAs can not be explained by miRNA expression difference between ER+ and ER- cancers.
###end p 45
###begin p 46
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 456 458 456 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 464 466 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 777 784 777 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
Several studies have reported that good classification of cancer subtypes can be achieved using the expression levels of miRNAs [13,14]. Because striking differences in the RE-scores for a set of miRNAs between ER+ and ER- samples are observed, the RE-score of an miRNA could be a promising predictor for breast cancer subtype classification. We used the RE-scores of the top eight significantly RE-changing miRNAs in the MN dataset [39] to classify the ER+ and ER- subtypes. As expected, the accuracy was up to 89.29%. The RE-score profiles of these miRNAs are plotted in Figure 6. The classification accuracy was comparable or even better (85.76%) when estimated using the expression levels of the top 35 differentially expressed miRNAs in the dataset published by Blenkiron et al. [30], suggesting that the prediction of ER status of breast cancer based on miRNA regulatory effect or miRNA targeted mRNA expression is an alternative to that based on miRNA expression.
###end p 46
###begin p 47
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 153 155 153 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 311 313 311 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
RE-score profiles of microRNAs for the classification of ER+ and ER- breast tumors. The figure demonstrates unsupervised hierarchical clustering of 57 ER+ and 42 ER- samples in the MN dataset [39] using the top 8 RE-changing miRNAs. A dendrogram of the tumors is shown at the top, with ER+ samples in red and ER- samples in yellow. For hierarchical clustering, RE-scores of each miRNA were mean centered and normalized, and tumors were clustered using Pearson correlation (uncentered) and average linkage (CLUSTER and TREEVIEW software) [73].
###end p 47
###begin title 48
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Differential expression of miRNA processing genes between ER+ and ER- breast cancers
###end title 48
###begin p 49
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 415 417 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
In addition to miRNA abundance, post-transcriptional regulation of miRNA expression may also be important for the inhibitory effect of miRNAs on their targets. Deregulation of genes required for miRNA biogenesis may be expected to lead to global changes in miRNA expression as well as the inhibitory effects of miRNAs. Therefore, we examined whether miRNA processing genes are differentially expressed in ER+ and ER- breast cancers.
###end p 49
###begin p 50
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago1 </italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 99 101 99 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 115 117 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRBP </italic>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
###xml 383 387 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago1</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 422 424 422 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 521 528 521 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1394 1396 1394 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1397 1399 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1400 1402 1400 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1467 1469 1467 1469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1643 1649 1643 1649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 1653 1657 1653 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago </italic>
###xml 1688 1690 1688 1690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1696 1698 1696 1698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1874 1876 1874 1876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1905 1912 1905 1912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1918 1924 1918 1924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 1955 1957 1955 1957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1047 1052 <span type="species:ncbi:9606">human</span>
###xml 1211 1216 <span type="species:ncbi:9606">human</span>
We found that among the miRNA processing genes, Ago1 and Ago2 were significantly up-regulated in ER- compared to ER+ samples in all datasets, with combined P-values of 4.0E-8 and 2.0E-10, respectively, whereas Dicer and TRBP were significantly down-regulated, with combined P-values of 8.8E-6 and 2.9E-10, respectively (Figure 7b; Additional data file 4). Differential expression of Ago1, Ago2 and Dicer between ER+ and ER- breast cancer has been previously investigated and consistent results were reported by Blenkiron et al. [30]. As shown in Figure 7a, several proteins play a critical role in the miRNA processing pathway. DROSHA, a double-stranded RNA-specific ribonuclease, digests the pri-miRNA in the nuclease to release hairpin, precursor miRNA (pre-miRNA) [7]; then DICER, a member of the RNase III nuclease, cleaves the pre-miRNA into a single-stranded mature miRNA with the assistance of TRBP [59]; finally, the mature miRNA is incorporated into RISC consisting of DICER, TRBP, AGO and several other proteins [60-62]. Among the eight human AGO proteins, AGO1 and AGO2 are known to play the most important roles in transcriptional silencing mediated by miRNAs or small interfering RNAs. Assembly of human RISC minimally requires AGO2, DICER, and TRBP, among which AGO2 is the catalytic engine owing to its endonuclease activity and the DICER-TRBP complex acts simply as a platform [60,63,64]. The relatively lower abundance of AGO1 and AGO2 proteins in ER+ breast cancer may limit the activity of functional RISC, which would in turn lower the inhibitory effect of miRNAs on their targets. Moreover, since the expression levels of Dicer and Ago genes are anti-correlated in ER+ and ER- cancer, there is no necessary link between the mature miRNA expression levels and RISC activity. This may also explain the global up-regulation of miRNA expression levels in ER+ cancer observed by Blenkiron et al. since Dicer is significantly up-regulated [30].
###end p 50
###begin p 51
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 93 97 93 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 193 195 193 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 209 211 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosha </italic>
###xml 382 384 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 390 392 390 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 401 405 401 405 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago1</italic>
###xml 432 436 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2</italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer</italic>
###xml 449 454 449 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRBP </italic>
###xml 459 461 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 695 696 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Differential expression of miRNA processing genes between ER+ and ER- breast cancer samples. (a) miRNA biogenesis and function pathway. Genes significantly up-regulated and down-regulated in ER- compared to ER+ samples are shown in yellow and cyan, respectively. A gene - for example, Drosha - is marked grey to denote that it shows no significant differential expression between ER- and ER+ samples. (b) Expression levels of Ago1, Ago2, Dicer, and TRBP in ER+ (red) and ER- (green) samples. The mean and the standard deviation of the expression levels for each gene are shown as a bar and vertical line, respectively. Data for a gene are not shown if it is missing from a dataset. The combined P-value for each gene is also shown.
###end p 51
###begin p 52
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRBP</italic>
###xml 416 418 416 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 432 434 432 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 635 642 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 709 711 709 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 717 719 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1367 1369 1367 1369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1436 1438 1436 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1804 1813 1804 1813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1847 1849 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1822 1827 <span type="species:ncbi:10090">mouse</span>
It seems that the key genes in the microRNA biogenesis pathway are subjected to delicate regulation and their differential expression is likely to be associated with distinct tumor subtypes. More interestingly, genes in this pathway are not consistently regulated: Dicer and TRBP, which are involved in miRNA maturation and RISC assembly, are down-regulated whereas the catalytic engine of RISC is up-regulated in ER- relative to ER+ breast cancer. As a result, the capability of miRNAs (or more precisely RISC) to repress their targets may not be reflected by their expression levels. Using microRNA microarray experiments, Blenkiron et al. [30] found that the most differentially expressed miRNAs between ER+ and ER- cancers are down-regulated in the latter. They also examined the correlation between miRNA expression and changes in the mRNA levels of their direct targets but failed to detect enrichment for down- or up-regulation of predicted target miRNAs consistent with miRNA expression differentiation in most cases. This can be explained by the hypothesis that many miRNAs act at the level of translation rather than mRNA stability; nevertheless, this can also be explained by discordance in changes of expression between the key miRNA processing genes. Our results demonstrate that miRNAs tend to have stronger inhibitory effect on their mRNA targets in ER- breast cancer, suggesting that the AGO proteins (up-regulated in ER- cancer at the mRNA level), the catalytic engine of RISC, may eventually determine the efficiency of miRNAs to down-regulate their targets. In addition, deregulation of the key genes in the miRNA biogenesis pathway may be related to tumorigenesis of certain cancer types, as has been suggested by the fact that down-regulating DICER expression promoted tumorigenesis in vitro and in a mouse lung cancer model [65].
###end p 52
###begin p 53
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 315 317 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 322 324 322 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2</italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 453 455 453 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 535 540 535 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 558 560 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 723 725 723 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 798 800 798 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 827 832 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 849 856 849 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 924 929 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 945 947 945 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1054 1058 1054 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2</italic>
###xml 1087 1095 1087 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-206 </italic>
###xml 1125 1130 1125 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 1146 1154 1146 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-206 </italic>
###xml 1205 1212 1205 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-206</italic>
###xml 1295 1303 1295 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-206 </italic>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 1524 1529 1524 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 1655 1657 1655 1657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1756 1758 1756 1758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
It has been reported that Ago2 is expressed more in ER- than in ER+ breast cancer cell lines, and that this is correlated with active ER signaling [66]. AGO2 enhances cell proliferation, reduces cell-cell adhesion, and increases cell migratory ability, which contribute to the tumor phenotype transformation from ER+ to ER- through overexpression of Ago2. Either gene amplification or activation of cell signaling cascades elevates Ago2 expression in ER- cancer cells. Up to now, no clear evidence or experimental data have shown that Ago2 is amplified in ER- cancer. The epidermal growth factor receptor (EGFR) and mitogen activated protein kinase (MAPK) signaling cascades are the major signal transduction pathways in ER- breast cancers [67,68]. One of the frequent and remarkable features in ER- cancer is the up-regulated EGFR gene [69]. Adams et al. [66] proposed and confirmed that epidermal growth factor stimulated Ago2 expression in ER- cancers and that this was primarily regulated by the MAPK pathway. In addition, with the overexpression of Ago2, the inhibition activity of miR-206 was elevated, whereas without Ago2 the activity of miR-206 remained unchanged even with the overexpression of miR-206, suggesting that formation of Ago2-miRNA complexes is the main factor influencing miR-206 inhibitory activity [70]. This is consistent with our finding that the activity of a microRNA cannot be explained merely by its expression level. Based on this suggestion, a hypothesis can be provided that, with elevated Ago2 expression, an miRNA's inhibitory activity accordingly increases, which leads to low expression levels of genes involved in ER+ cell types and the predominant expression of genes involved in the oncogenic pathways leading to ER- cancer.
###end p 53
###begin p 54
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer</italic>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 466 468 466 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 556 562 556 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 628 634 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 639 641 639 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 896 898 896 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 905 907 905 907 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 923 929 923 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 978 980 978 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 994 996 994 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Despite growing evidence that Dicer mRNA levels vary between different tumor subtypes and that these variations are correlated with cancer progression [53-55], the regulation of Dicer remains unclear. Weisen et al. [56] reported that type I interferon represses Dicer. As already reported, MAPK signaling pathways comprise a major cascade in ER- cancers [68]. Type I interferon signals can be transduced by the MAPK pathway [71], and the activated MAPK pathway in ER- cancers may enhance the signal of type I interferon, which results in the inhibition of Dicer expression. Another possible explanation of the low expression of Dicer in ER- cancers may be the regulatory effect of miRNAs. DICER's epigenetic regulation could also occur via specific mechanisms involving the DICER 3' UTR and the binding of microRNAs [56]. In this study, we have shown that the activity of miRNAs is stronger in ER- than ER+ cancer and that Dicer is targeted and suppressed to a lower level in ER- compared to ER+ cancers.
###end p 54
###begin title 55
Conclusions
###end title 55
###begin p 56
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 425 427 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 434 436 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1178 1180 1178 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1323 1325 1323 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1331 1333 1331 1333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1348 1353 1348 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago1 </italic>
###xml 1357 1362 1357 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ago2 </italic>
###xml 1398 1400 1398 1400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1414 1420 1414 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dicer </italic>
###xml 1424 1429 1424 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRBP </italic>
In this study, we created the RE-score to measure the inhibitory effect of a miRNA on its targets. Based on RE-score calculations, we compared the inhibitory effects of miRNAs on their targets between two breast cancer subtypes, ER+ and ER-. miRNAs that showed significantly different inhibitory effects were identified for five independent datasets. We found that, for most miRNAs, the target genes were more repressed in ER- than ER+ breast cancer, suggesting that miRNAs have stronger inhibitory abilities in the former. The exact identity of the miRNA targets does not seem important since these findings are robust to several distinct methods of miRNA target prediction and are further consolidated by another two methods for comparing miRNA regulation. To seek the potential mechanisms contributing to the inhibitory effects of miRNAs, we explored miRNA abundance measured by miRNA microarrays and expression levels of genes involved in miRNA biogenesis and function. Our analysis indicates that a high inhibitory ability is not necessarily associated with high miRNA expression levels, because previous miRNA expression data do not suggest prevalent over-expression in ER- breast cancer. However, it is interesting to find that several key miRNA processing genes are significantly differentially expressed between ER+ and ER- breast cancer. Ago1 and Ago2 are significantly up-regulated in ER- cancer, while Dicer and TRBP are significantly down-regulated. These results imply that the miRNA processing pathway is subject to subtle regulation and that deregulation of key genes in this is involved in the cancer pathology. This method is easily applied and can be used to investigate the miRNA regulation underlying other microarray datasets.
###end p 56
###begin title 57
Materials and methods
###end title 57
###begin title 58
Breast cancer microarray datasets
###end title 58
###begin p 59
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 336 338 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 381 383 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 714 716 714 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 722 724 722 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
All the microarray data used in this study were downloaded from public databases or from the websites provided by the original publications. Over ten breast cancer datasets have been generated in previous studies [33-41,44]. From these datasets, we chose five according to the following criteria: contain at least 30 samples for both ER+ and ER- breast cancer; and expression of ER+ and ER- samples is measured using the same platform. The first criterion is to ensure a high power of statistical analysis, while the second criterion is to avoid bias introduced by platform effect. Among these five datasets, one used cDNA arrays and the other four used oligonucleotide arrays produced by Affymetrix. Numbers of ER+ and ER- samples in each dataset are listed in Table 5. The expression values are represented by normalized log ratios for cDNA microarrays or by log-transformed intensities after Robust Multichip Average normalization for Affymetrix oligonucleotide microarrays [72]. The probe or probeset IDs are mapped to NCBI Refseq IDs. When multiple probe sets are mapped to the same Refseq ID, their values are averaged to represent the expression level of this Refseq gene.
###end p 59
###begin p 60
Breast cancer gene expression datasets used in this study
###end p 60
###begin title 61
miRNA target predictions
###end title 61
###begin p 62
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
A number of miRNA target prediction approaches have been suggested in the past few years [43,45-47]. In this paper, we utilize four sets of miRNA target prediction data derived using PITA [43], miRanda [46], PicTar [45] and TargetScan [3,47], respectively. All miRNA target prediction datasets were downloaded from the most recently updated websites. To facilitate the analysis, the target gene IDs were also converted into NCBI Refseq IDs. For each miRNA, the target genes are defined as those presented in the microarray data and predicted to contain at least one binding site at their 3' UTR; the non-target genes are defined as those presented in the microarray data but not predicted to be regulated by the miRNA.
###end p 62
###begin title 63
Measuring a miRNA's inhibitory effect with the average rank difference between its targets and non-targets
###end title 63
###begin p 64
To measure the inhibitory effect for a miRNA, we defined the RE-score, which measures the difference in expression levels between its target and non-target genes. The RE-score can be calculated in two ways: one is based on rank comparison and the other is based on expression comparison.
###end p 64
###begin p 65
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 126 128 126 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 126 128 126 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>t </italic></sub>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 133 134 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></sub>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 265 267 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 265 267 265 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>t </italic></sub>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 272 273 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></sub>
The RE-score based on rank comparison is calculated as follows. We denote the number of a miRNA's targets and non-targets as Nt and Nn, respectively. After sorting the expression levels of all genes, the ranks of target genes and a non-target genes are denoted as Rt and Rn, respectively. The RE-score of a miRNA is defined as the difference of the average rank between its targets and non-targets:
###end p 65
###begin p 66

###end p 66
###begin p 67
where  and  represent the mean target and non-target ranks, respectively. The RE-score is essentially a transformation of the sum rank statistic (the sum of ranks for target genes) used in the Wilcoxon rank sum test. Since genes with high absolute expression values have high rank values, a positive RE-score indicates that the non-target genes of a miRNA tend to be expressed at higher levels than its target genes, presumably due to the inhibitory effect of the miRNA on its target genes. The higher the RE-score, the stronger the inhibitory effect of a miRNA on its targets.
###end p 67
###begin title 68
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Identifying microRNAs with significantly changed RE-scores between ER+ and ER- breast cancer
###end title 68
###begin p 69
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 234 236 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 242 244 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
To investigate the difference of a miRNA regulatory effect between ER+ and ER- breast cancer, a two sample t-test was performed to compare RE-scores and determine whether the RE-scores of a miRNA are significantly different between ER+ and ER- cancer.
###end p 69
###begin p 70
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 215 217 215 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 219 221 219 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 226 228 226 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 353 356 353 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 369 372 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 433 435 433 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 489 491 489 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 556 558 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 601 604 601 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 621 624 621 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 638 641 638 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 712 715 712 715 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 817 820 817 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 827 830 827 830 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 837 840 837 840 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 908 911 906 909 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 932 935 928 931 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 947 950 941 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 995 998 989 992 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 1016 1019 1008 1011 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 1028 1031 1018 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
###xml 1052 1055 1042 1045 <sub xmlns:xlink="http://www.w3.org/1999/xlink">RES</sub>
Since usually hundreds of miRNAs are examined simultaneously, multiple testing corrections needed to be considered. We calculated the FDR based on permutations similar to the method used in SAM [42]. If there were N1 ER+ and N2 ER- samples, the t-scores obtained from comparing RE-scores for each miRNA were calculated in the original data, denoted as TRES(r) for the rth miRNA. We then permutated the samples; at each permutation, N1 samples were randomly selected to form one permuted ER+ group, and the rest of the samples were used as the permutated ER- group. The permutated t-score, denoted as TRES(r, k), for the rth miRNA in the kth permutation, is recalculated. We then considered the histogram of all TRES(r, k) over all r and k, and used this null distribution to compute an FDR value for a given t-score TRES(r) = TRES*. If TRES* >/= 0, the FDR is the ratio of the percentage of all (r, k) with TRES(r, k) >/= 0, whose TRES(r, k) >/= TRES*, divided by the percentage of miRNAs with TRES(r) >/= 0, where TRES(r) >/= TRES*, and similarly if TRES* < 0.
###end p 70
###begin p 71
If the FDR for a miRNA is below a predefined threshold, we call this miRNA as a significantly RE-changing miRNA.
###end p 71
###begin title 72
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
ER+ and ER- cancer subtype classification
###end title 72
###begin p 73
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 567 569 567 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 611 613 611 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 637 639 637 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 641 643 641 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 648 650 648 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 652 654 652 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 678 680 678 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 683 684 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 747 749 747 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 751 753 751 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 776 778 776 778 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 780 782 780 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 784 786 784 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 791 793 791 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 795 796 795 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
The miRNA RE-score is a promising feature to classify tumor subtypes as well as microRNA expression. In this study, we constructed a multi-miRNA signature and used the algorithm of a linear support vector machine. We ranked the P-values that were derived from the comparison of RE-scores or expressions. The top N significant RE-score changing microRNAs or differentially expressed microRNAs were chosen to perform the classification analysis. To estimate the effect of the classifier, we adapted a leave one out cross validation strategy. Generally, the number of ER+ samples is different from the number of ER- samples. If there were N1 ER+ and N2 ER- samples, assuming that N1 > N2, in order to balance the sample effect, we randomly selected N2 ER+ samples. The total 2* N2 (N2 ER+ and N2 ER-) samples were used in the leave one out validation. The classification accuracy was determined by averaging the accuracies of the leave one out validations repeated 100 times.
###end p 73
###begin title 74
Abbreviations
###end title 74
###begin p 75
ARR: adapted ranked ratio; ER: estrogen receptor; FDR: false discovery rate; MAPK: mitogen activated protein kinase; miRNA: microRNA; RE: regulatory effect; RISC: RNA-induced silencing complex; RR: ranked ratio; SAM: significance analysis of microarrays; UTR: untranslated region.
###end p 75
###begin title 76
Authors' contributions
###end title 76
###begin p 77
CC and MG conceived and designed the study. CC extracted the gene expression data. CC and XF preformed the full analysis. CC, XF, PA and MG wrote the manuscript.
###end p 77
###begin title 78
Additional data files
###end title 78
###begin p 79
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 492 494 492 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 500 502 500 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
The following additional data are available with the online version of this paper: a figure showing distributions of miRNA target numbers determined using different prediction tools (Additional data file 1); a table listing RE-score results for five breast cancer expression datasets (Additional data file 2); a table listing RE-score results calculated using the expression comparison method (Additional data file 3); a table listing expression levels of several miRNA processing genes in ER+ and ER- samples (Additional data file 4).
###end p 79
###begin title 80
Supplementary Material
###end title 80
###begin title 81
Additional data file 1
###end title 81
###begin p 82
Distribution of miRNA target numbers for four prediction tools, PITA, miRanda, PicTar, and TargetScan. In addition, three different parameters in TargetScan were chosen and are denoted as 'Conserved', 'ContextScore >/= -0.20' and 'All', respectively. On average, 6,949, 2,026, 1,563, 765, 426, and 210 targets per miRNA were predicted by PITA, TargetScan(All), miRanda, TargetScan(ContextScore >/= -0.20), PicTar, and TargetScan(Conserved), respectively.
###end p 82
###begin p 83
Click here for file
###end p 83
###begin title 84
Additional data file 2
###end title 84
###begin p 85
###xml 302 303 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 324 325 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Includes seven sheets containing the complete results based on RE-scores from rank comparison and seven miRNA target predictions from PITA, miRanda, PicTar, the intersection of PITA and miRanda, TargetScan(Conserved), TargetScan(ContextScore >/= -0.20), and TargetScan(All), respectively. The t-score, P-value, and adjusted P-value (FDR) of all miRNAs in the five breast cancer datasets are provided.
###end p 85
###begin p 86
Click here for file
###end p 86
###begin title 87
Additional data file 3
###end title 87
###begin p 88
Additional data file 3 includes two sheets containing the complete results based on RE-scores calculated from expression comparison. In the two sheets, miRNA target predictions determined by the miRanda and PITA tools are used, respectively.
###end p 88
###begin p 89
Click here for file
###end p 89
###begin title 90
Additional data file 4
###end title 90
###begin p 91
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Expression levels of several miRNA processing genes in ER+ and ER- samples.
###end p 91
###begin p 92
Click here for file
###end p 92
###begin title 93
Acknowledgements
###end title 93
###begin p 94
We acknowledge support from the NIH and from the AL Williams Professorship funds.
###end p 94
###begin article-title 95
MicroRNAs: genomics, biogenesis, mechanism, and function.
###end article-title 95
###begin article-title 96
microRNAs: tiny regulators with great potential.
###end article-title 96
###begin article-title 97
###xml 81 86 <span type="species:ncbi:9606">human</span>
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
###end article-title 97
###begin article-title 98
###xml 24 29 <span type="species:ncbi:9606">human</span>
Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis.
###end article-title 98
###begin article-title 99
MicroRNAs and the regulation of cell death.
###end article-title 99
###begin article-title 100
Developmental biology. Encountering microRNAs in cell fate signaling.
###end article-title 100
###begin article-title 101
MicroRNAs modulate hematopoietic lineage differentiation.
###end article-title 101
###begin article-title 102
###xml 23 28 <span type="species:ncbi:9606">human</span>
MicroRNA signatures in human cancers.
###end article-title 102
###begin article-title 103
Oncomirs - microRNAs with a role in cancer.
###end article-title 103
###begin article-title 104
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.
###end article-title 104
###begin article-title 105
RAS is regulated by the let-7 microRNA family.
###end article-title 105
###begin article-title 106
miR-15 and miR-16 induce apoptosis by targeting BCL2.
###end article-title 106
###begin article-title 107
###xml 38 43 <span type="species:ncbi:9606">human</span>
MicroRNA expression profiles classify human cancers.
###end article-title 107
###begin article-title 108
MicroRNAs accurately identify cancer tissue origin.
###end article-title 108
###begin article-title 109
###xml 62 84 62 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans</italic>
###xml 62 84 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans
###end article-title 109
###begin article-title 110
Repression of protein synthesis by miRNAs: how many mechanisms?
###end article-title 110
###begin article-title 111
The widespread impact of mammalian MicroRNAs on mRNA repression and evolution.
###end article-title 111
###begin article-title 112
Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution.
###end article-title 112
###begin article-title 113
###xml 45 50 <span type="species:ncbi:9606">human</span>
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals.
###end article-title 113
###begin article-title 114
Silencing of microRNAs in vivo with 'antagomirs'.
###end article-title 114
###begin article-title 115
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation.
###end article-title 115
###begin article-title 116
MicroRNAs direct rapid deadenylation of mRNA.
###end article-title 116
###begin article-title 117
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.
###end article-title 117
###begin article-title 118
Systematic identification of microRNA functions by combining target prediction and expression profiling.
###end article-title 118
###begin article-title 119
Individual mRNA expression profiles reveal the effects of specific microRNAs.
###end article-title 119
###begin article-title 120
Inferring microRNA activities by combining gene expression with microRNA target prediction.
###end article-title 120
###begin article-title 121
###xml 118 129 118 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
###xml 118 128 <span type="species:ncbi:7227">Drosophila</span>
Global analysis of microRNA target gene expression reveals that miRNA targets are lower expressed in mature mouse and Drosophila tissues than in the embryos.
###end article-title 121
###begin article-title 122
###xml 21 26 <span type="species:ncbi:9606">women</span>
Clinical options for women at high risk for breast cancer.
###end article-title 122
###begin article-title 123
###xml 35 40 <span type="species:ncbi:9606">human</span>
A microRNA expression signature of human solid tumors defines cancer gene targets.
###end article-title 123
###begin article-title 124
###xml 33 38 <span type="species:ncbi:9606">human</span>
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.
###end article-title 124
###begin article-title 125
###xml 41 46 <span type="species:ncbi:9606">human</span>
MicroRNA gene expression deregulation in human breast cancer.
###end article-title 125
###begin article-title 126
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.
###end article-title 126
###begin article-title 127
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours.
###end article-title 127
###begin article-title 128
Gene expression profiling predicts clinical outcome of breast cancer.
###end article-title 128
###begin article-title 129
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.
###end article-title 129
###begin article-title 130
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
###end article-title 130
###begin article-title 131
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
###end article-title 131
###begin article-title 132
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
###end article-title 132
###begin article-title 133
Genes that mediate breast cancer metastasis to lung.
###end article-title 133
###begin article-title 134
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
###end article-title 134
###begin article-title 135
###xml 42 47 <span type="species:ncbi:9606">human</span>
X chromosomal abnormalities in basal-like human breast cancer.
###end article-title 135
###begin article-title 136
Significance analysis of microarrays applied to the ionizing radiation response.
###end article-title 136
###begin article-title 137
The role of site accessibility in microRNA target recognition.
###end article-title 137
###begin article-title 138
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
###end article-title 138
###begin article-title 139
Combinatorial microRNA target predictions.
###end article-title 139
###begin article-title 140
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human microRNA targets.
###end article-title 140
###begin article-title 141
Prediction of mammalian microRNA targets.
###end article-title 141
###begin article-title 142
MicroRNA targeting specificity in mammals: determinants beyond seed pairing.
###end article-title 142
###begin article-title 143
The impact of microRNAs on protein output.
###end article-title 143
###begin article-title 144
MicroRNAs: target recognition and regulatory functions.
###end article-title 144
###begin article-title 145
Most mammalian mRNAs are conserved targets of microRNAs.
###end article-title 145
###begin article-title 146
###xml 55 60 <span type="species:ncbi:9606">human</span>
The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.
###end article-title 146
###begin article-title 147
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Dicer, Drosha, and outcomes in patients with ovarian cancer.
###end article-title 147
###begin article-title 148
Overexpression of Dicer in precursor lesions of lung adenocarcinoma.
###end article-title 148
###begin article-title 149
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Reduced expression of Dicer associated with poor prognosis in lung cancer patients.
###end article-title 149
###begin article-title 150
Dicer is regulated by cellular stresses and interferons.
###end article-title 150
###begin article-title 151
###xml 56 61 <span type="species:ncbi:9606">human</span>
Relief of microRNA-mediated translational repression in human cells subjected to stress.
###end article-title 151
###begin article-title 152
MicroRNA responses to cellular stress.
###end article-title 152
###begin article-title 153
###xml 102 112 102 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 102 112 <span type="species:ncbi:6239">C. elegans</span>
Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans
###end article-title 153
###begin article-title 154
TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing.
###end article-title 154
###begin article-title 155
Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression.
###end article-title 155
###begin article-title 156
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing.
###end article-title 156
###begin article-title 157
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 31 36 <span type="species:ncbi:9606">human</span>
In vitro reconstitution of the human RISC-loading complex.
###end article-title 157
###begin article-title 158
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.
###end article-title 158
###begin article-title 159
Impaired microRNA processing enhances cellular transformation and tumorigenesis.
###end article-title 159
###begin article-title 160
Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.
###end article-title 160
###begin article-title 161
Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia.
###end article-title 161
###begin article-title 162
Integrating signals from RTKs to ERK/MAPK.
###end article-title 162
###begin article-title 163
Untangling the ErbB signalling network.
###end article-title 163
###begin article-title 164
The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ER{alpha}) signaling and a luminal phenotype in MCF-7 breast cancer cells.
###end article-title 164
###begin article-title 165
Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway.
###end article-title 165
###begin article-title 166
Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
###end article-title 166
###begin article-title 167
Cluster analysis and display of genome-wide expression patterns.
###end article-title 167

